Resveratrol Inhibitory Effects against a Malignant Tumor: A Molecular Introductory Review

Polyphenols in Human Health and Disease

Volumn 2, Issue , 2013, Pages 1269-1281

  Wcislo, Gabriel ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Apoptosis; Cancer inhibition; Cell cycle; Cell cytoskeleton; Resveratrol

Indexed keywords

EID: 84902555075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398456-2.00096-7     Document Type: Chapter

References (106)

1. Goswami S.K., Das D.K. Resveratrol and chemoprevention. Cancer Lett 2009, 284(1):1-6.
2. Cimino S., Sortino G., Favilla V., Castelli T., Madonia M., Sansalone S., et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012, 2012:632959.
3. Das D.K., Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006, 6(1):36-47.
4. Rimando A.M., Cuendet M., Desmarchelier C., Mehta R.G., Pezzuto J.M., Duke S.O., et al. Cancer chemopreventive and antioxidant activities of pterostilbene a naturally occurring analogue of resveratrol. J Agric Food Chem 2002, 50(12):3453-3457.
5. Wolter F., Clausnitzer A., Akoglu B., Stein J. Piceatannol a natural analog of resveratrol inhibits progression through the S-phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002, 132(2):298-302.
6. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., et al. The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CVP1B1. Br J Cancer 2002, 86(5):774-778.
7. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339(8808):1523-1526.
8. Nonomura S., Kanagawa H., Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of ko-jo-kon. Yakugaku Zassi 1963, 83:988-990.
9. Nunes T., Almeida L., Rocha J.F., Falcão A., Fernandes-Lopes C., Loureiro A.I., et al. Pharmacokinetis of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 2009, 49(12):1477-1482.
10. Vaz-da-Silva M., Loureiro A.I., Falcao A., Nunes T., Rocha J.F., Fernandes-Lopes C., et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008, 46(11):564-570.
11. Shankar S., Singh G., Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007, 12:4839-4854.
12. Guo L., Peng Y., Yao J., Sui L., Gu A., Wang J. Anticancer activity and molecular mechanisms of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm 2010, 25(4):471-477.
13. Shao J., Li X., Lu X., Jiang C., Hu Y., Li Q., et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces 2009, 72(1):40-47.
14. Weinberg R.A. How cancer arises. Sci Am 1996, 275(3):62-70.
15. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. New Engl J Med 2002, 347(20):1593-1603.
16. Lieberman M.W., Neoplasia Lebovitz R.M. Anderson's Pathology 1996, 513-547. Mosby. 10th ed. I. Damjanov, J. Linder (Eds.).
17. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68(9):3077-3080.
18. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400(6743):464-468.
19. Hahn W.C., Weinberg R.A. Modeling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2(5):331-341.
20. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol 2000, 18(13):2626-2634.
21. Wong J.M.Y., Collins K. Telomere maintenance and disease. Lancet 2003, 362(9388):983-988.
22. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Falchetti R., et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol 2006, 28(3):641-648.
23. Campisi J. Cancer and ageing: rival demons?. Nat Rev Cancer 2003, 3(5):339-349.
24. Bernards R., Weinberg R.A. A progression puzzle. Nature 2002, 418(6900):823.
25. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411(6835):375-379.
26. Nelson C.M., Bissell M.J. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006, 22:287-309.
27. Anderson A.R.A., Weaver A.M., Cummings P.T., Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127(5):905-915.
28. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 18(21):1182-1186.
29. Folkman J. Clinical application of research on angiogenesis. New Engl J Med 1995, 333(26):1757-1763.
30. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9(4):239-252.
31. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
32. Sotgia F., Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Lisanti M.P. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 2011, 13(4):213-226.
33. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033.
34. Muqbil I., Beck F.W., Bao B., Sarkar F.H., Mohammad R.M., Hadi S.M., et al. Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Curr Pharm Des 2012, 18(12):1645-1654.
35. Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumour immunity: Effector response to tumour and role of the micro environment. Lancet 2008, 371(9614):771-783.
36. Ghiringhelli F., Rebe C., Hicami A., Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem 2012, 12(8):852-873.
37. Salado C., Olaso E., Gallot N., Valcarcel M., Egilegor E., Mendoza L., et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med 2011, 9:59-70.
38. Holland A.J., Cleveland D.W. Bovery revised: chromosomal instability, aneuploidity and tumorigenesis. Nat Rev Mol Cell Biol 2009, 10(7):478-487.
39. Quackenbush J. Microarray analysis and tumor classification. New Engl J Med 2006, 354(23):2463-2472.
40. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33(1):49-54.
41. Ioannidis J.P. Is molecular profiling ready for use in clinical decision make?. Oncologist 2007, 12(3):301-311.
42. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., et al. Laser capture microdissection. Science 1996, 274(5289):998-1001.
43. Rubin M.A. Tech.Sight. Understanding disease cell by cell. Science 2002, 296(5571):1329-1330.
44. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., Petronio M., Polzer B., Stoecklein N.H., et al. Genetic heterogeneity of single disseminated tumour cells in minima residua cancer. Lancet 2002, 360(9334):683-689.
45. Hudson K.L. Genomics, health care, and society. New Engl J Med 2011, 365(11):1033-1041.
46. Goldstein D.B., Tate S.K., Sisodiya S.M. Pharmacogenetics goes genomic. Nat Rev Genet 2003, 4(12):937-947.
47. Ulrich C.M., Robien K., McLeod H.L. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003, 3(12):912-920.
48. Yang S.H., Kim J.S., Oh T.J., Kim M.S., Lee S.W., Woo S.K., et al. Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Cancer 2003, 22(4):741-750.
49. Narayanan B.A., Narayanan N.K., Re G.G., Nixon D.W. Differential expression of genes indiced by resveratrol in LNCAP cells: p53-mediated molecular targets. Int J Cancer 2003, 104(2):204-212.
50. Shi T., Liou L.S., Sadhukhan P., Duan Z.H., Novick A.C., Hissong J.G., et al. Effects of resveratrol on gene expression in renal cell carcinoma. Cancer Biol Ther 2004, 3(9):882-888.
51. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 2000, 247(1-2):1-15.
52. Molumbres M., Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Develop 2007, 17(1):60-65.
53. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24(11):1770-1783.
54. Clarke P.R., Allan L.A. Cell-cycle control in the face of damage - a matter of life or death. Trends Cell Biol 2009, 19(3):89-98.
55. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1998, 421(3):277-279.
56. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., Mukhtar H. Resveratrol causes Waf-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7(5):1466-1473.
57. Adhami V.M., Afaq F., Ahmad N. Involvement of the retinoblastoma pRb-E2F/PR pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun 2001, 288(3):579-585.
58. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., Reddy G.P. Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis. Cancer Res 2002, 62(9):2488-2492.
59. Joe A.K., Liu H., Suzui M., Vural M.E., Xiao D., Weinstein I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker in several human cancer cell lines. Clin Cancer Res 2002, 8(3):893-903.
60. Hsieh T.C., Burfeind P., Laud K., Backer J.M., Traganos F., Darzynkiewicz Z., et al. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol 1999, 15(2):245-252.
61. Slack J.W.M. Stem cells in epithelial tissues. Science 2000, 287(5457):1431-1433.
62. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
63. Shankar S., Nall D., Tang S.N., Meeker D., Passarini J., Sharma J., et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011, 6(1):e16530.
64. Bode A.M., Dong Z. Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol 2003, 36(1):66-77.
65. Aggarwal B.B. Nuclear factorκB: the enemy within. Cancer Cell 2004, 6(3):203-208.
66. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71(10):1397-1421.
67. Bohmann D., Bos T.J., Admon A., Nishimura T., Vogt P.K., Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987, 238(4832):1386-1392.
68. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3(11):859-868.
69. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NFκB, AP-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164(12):6509-6519.
70. Gullett N.P., Ruhul Amin A.R., Bayraktar S., Pezzuto J.M., Shin D.M., Khuri F.R., et al. Cancer prevention with natural compounds. Semin Oncol 2010, 37(3):258-281.
71. Saini S., Majid S., Dahiya R. Diet, micro RNAs and prostate cancer. Pharm Res 2010, 27(6):1014-1026.
72. Bartel D.P., Chen C.Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Gent 2004, 5(5):396-400.
73. Tili E., Michaille J.J., Adair B., Alder H., Limagne E., Taccioli C., et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010, 31(9):1561-1566.
74. Pollard T.D., Borisy G.G. Cellular motility driver by assembly and disassembly of action filaments. Cell 2003, 112(4):453-465.
75. Faix J., Rottner K. The making of filopodia. Curr Opin Cell Biol 2006, 18(1):18-25.
76. Kozma R., Ahmed S., Best A., Lim L. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral action microspikes and filopodia in Swiss 3T3 fibroblasts. Mol Cell Biol 1995, 15(4):1942-1952.
77. Faix J., Breitsprecher D., Stradal T.E., Rottner K. Filopodia: complex models for simple rods. Int J Biochem Cell Biol 2009, 41(8-9):1656-1664.
78. Mattila P.K., Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 2008, 9(6):446-454.
79. Azios N.G., Krishnamoorthy L., Harris M., Cubano L.A., Cammer M., Dharmawardhane S.F. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the action cytoskeleton of metastatic breast cancer cells. Neoplasia 2007, 9(2):147-158.
80. Azios N.G., Dharmawardhane S.F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 2005, 7(2):128-140.
81. Rodrigue C.M., Porteu F., Navarro N., Bruyneel E., Bracke M., Romeo P.H., et al. The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities. Oncogene 2005, 24(20):3274-3284.
82. Degterev A., Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008, 9(5):378-390.
83. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008, 8(2):121-132.
84. Lindsay J., Esposti M.D., Gilmore A.P. Bcl-2 proteins and mitochondria - specificity in membrane targeting of death. Biochim Biophys Acta 2011, 1813(4):532-539.
85. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A):2783-2840.
86. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71(10):1397-1421.
87. Clement M.-V., Hirpara J.L., Chawdhury S.-H., Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998, 92(3):996-1002.
88. Delmas D., Rébé C., Lacour S., Filomenko R., Athias A., Gambert P., et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003, 278(42):41482-41490.
89. Delmas D., Rébé C., Micheau O., Athias A., Gambert P., Grazide S., et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004, 23(55):8979-8986.
90. Sareen D., van Ginkel P.R., Takach J.C., Mohiuddin A., Darjatmoko S.R., Albert D.M., et al. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci 2006, 47(9):3708-3716.
91. Dorrie J., Gerauer H., Wachter Y., Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 2001, 61(12):4731-4739.
92. Jiang H., Zhang L., Kuo J., Kuo K., Gautam S.C., Groc L., et al. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther 2005, 4(4):554-561.
93. Shamim U., Hanif S., Albanyan A., Beck F.W., Bao B., Wang Z., et al. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol 2012, 227(4):1493-1500.
94. Suttana W., Mankhetkorn S., Poompimon W., Palagani A., Zhokhov S., Gerlo S., et al. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer 2010, 9:99.
95. Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 2011, 1215:150-160.
96. Bharti A.C., Aggarval B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002, 64(5-6):883-888.
97. Singh N., Nigam M., Ranjan V., Zaidi D., Garg V.K., Sharma S., et al. Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants. Cancer Sci 2011, 102(5):1059-1067.
98. Liao H.F., Kuo C.D., Yang Y.C., Lin C.P., Tai H.C., Chen Y.Y., et al. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H383 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res 2005, 46(4):387-393.
99. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421.
100. Kundu J.K., Surh Y.-J. Cancer chemoprevention and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008, 269(2):243-261.
101. Landis-Piwowar K.R., Milacic V., Chen D., Yang H., Zhao Y., Chan T.H., et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 2006, 9(6):263-273.
102. Vyas S., Asmerom Y., De Leon D.D. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology 2005, 146(10):4224-4233.
103. Choi H.K., Yang J.W., Kang K.W. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett 2006, 242(2):198-206.
104. Cal C., Garban H., Jazirehi A., Yeh C., Mizutani Y., Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemoimmunosensitizing activities. Curr Med Chem Anticancer Agents 2003, 3(2):77-93.
105. Takaoka M. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. Fil.). J Faculty Sci Hokkaido Imperial University 1940, 3:1-16.
106. Mattson M.P. Dietary factors, hormesis and health. Ageing Res Rev 2008, 7(1):43-48.